scholarly journals Temozolomide induced bone marrow Suppression-A single institution outcome analysis and review of the literature

2015 ◽  
Vol 90 (9) ◽  
pp. E183-E184 ◽  
Author(s):  
Taxiarchis V. Kourelis ◽  
Jan C. Buckner ◽  
Naseema Gangat ◽  
Mrinal M. Patnaik
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Suppression ◽  
Outcome Analysis ◽  
Review Of The Literature ◽  
Single Institution

Methotrexate-Induced Cutaneous Ulcers in a Nonpsoriatic Patient: Case Report and Review of the Literature

2011 ◽  
Vol 15 (5) ◽  
pp. 275-279 ◽  
Author(s):  
Anil Kurian ◽  
Richard Haber
Keyword(s):  
Rheumatoid Arthritis ◽  
Bone Marrow ◽  
Complete Healing ◽  
Bone Marrow Suppression ◽  
Review Of The Literature ◽  
Patient Case ◽  
Antimitotic Agent ◽  
Autoimmune Conditions ◽  
History Of

Background: Methotrexate is a mainstay of treatment for autoimmune conditions such as rheumatoid arthritis and psoriasis. Methotrexate has numerous potential side effects and, in rare circumstances, can lead to cutaneous ulceration. Methotrexate can cause skin ulceration, and stopping this medication can lead to complete healing of the ulcerated lesion. Observations: A 67-year-old man with rheumatoid arthritis on long-term methotrexate therapy presented to hospital with ulcers on his hands, elbows, and lower extremities. He had no history of psoriasis. Shortly after admission, the patient was noted to have pancytopenia. A bone marrow biopsy showed a hypocellular marrow. Both the cutaneous ulcers and the hypocellular marrow were thought to be induced by methotrexate. The ulcerated areas were biopsied, and histopathology showed no evidence of vasculitis. After 1 month of rehabilitative skin care, the patient's ulcers healed almost completely and his bone marrow suppression recovered. Conclusion: We report the fifth case of methotrexate-induced cutaneous ulceration in a nonpsoriatic patient and review the literature on this unusual drug reaction. Methotrexate can induce cutaneous ulceration in nonpsoriatic patients and should be considered a potential cause of ulceration in patients treated with this antimitotic agent.

Thalidomide in Children Undergoing Bone Marrow Transplantation: Series at a Single Institution and Review of the Literature

PEDIATRICS ◽  
1999 ◽  
Vol 103 (4) ◽  
pp. e44-e44 ◽  
Author(s):  
Paulette Mehta ◽  
Amos Kedar ◽  
John Graham-Pole ◽  
Suzanne Skoda-Smith ◽  
John R. Wingard
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Review Of The Literature ◽  
Single Institution

scholarly journals Severe bone marrow suppression due to methotrexate toxicity following aceclofenac-induced acute kidney injury

2018 ◽  
pp. bcr-2018-224722 ◽  
Author(s):  
Robin George Manappallil ◽  
Durga Prasan ◽  
Jayameena Peringat ◽  
Illolil Kuniyil Biju
Keyword(s):  
Bone Marrow ◽  
Acute Kidney Injury ◽  
Kidney Injury ◽  
Bone Marrow Suppression ◽  
Methotrexate Toxicity

scholarly journals Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy

2021 ◽  
Vol 9 (5) ◽  
pp. e001743
Author(s):  
Abraham Nissani ◽  
Shaked Lev-Ari ◽  
Tomer Meirson ◽  
Elad Jacoby ◽  
Nethanel Asher ◽  
...  
Keyword(s):  
Bone Marrow ◽  
T Cell ◽  
Adverse Events ◽  
Cell Therapy ◽  
Clinical Response ◽  
Serum Levels ◽  
Bone Marrow Suppression ◽  
Maximum Effect ◽  
Operating Characteristics ◽  
Lymphocyte Ratio

BackgroundAdoptive cell therapy with T cells genetically engineered to express a chimeric antigen receptor (CAR-T) or tumor-infiltrating T lymphocytes (TIL) demonstrates impressive clinical results in patients with cancer. Lymphodepleting preconditioning prior to cell infusion is an integral part of all adoptive T cell therapies. However, to date, there is no standardization and no data comparing different non-myeloablative (NMA) regimens.MethodsIn this study, we compared NMA therapies with different doses of cyclophosphamide or total body irradiation (TBI) in combination with fludarabine and evaluated bone marrow suppression and recovery, cytokine serum levels, clinical response and adverse events.ResultsWe demonstrate that a cumulative dose of 120 mg/kg cyclophosphamide and 125 mg/m2 fludarabine (120Cy/125Flu) and 60Cy/125Flu preconditioning were equally efficient in achieving deep lymphopenia and neutropenia in patients with metastatic melanoma, whereas absolute lymphocyte counts (ALCs) and absolute neutrophil counts were significantly higher following 200 cGyTBI/75Flu-induced NMA. Thrombocytopenia was most profound in 120Cy/125Flu patients. 30Cy/75Flu-induced preconditioning in patients with acute lymphoblastic leukemia resulted in a minor ALC decrease, had no impact on platelet counts and did not yield deep neutropenia. Following cell infusion, 120Cy/125Flu patients with objective tumor response had significantly higher ALC and significant lower inflammatory indexes, such as neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR). Receiver-operating characteristics curve analysis 7 days after cell infusion was performed to determine the cut-offs, which distinguish between responding and non-responding patients in the 120Cy/125Flu cohort. NLR≤1.79 and PLR≤32.7 were associated with clinical response and overall survival. Cytokine serum levels did not associate with clinical response in patients with TIL. Patients in the 120Cy/125Flu cohort developed significantly more acute NMA-related adverse events, including thrombocytopenia, febrile neutropenia and cardiotoxicity, and stayed significantly longer in hospital compared with the 60Cy/125Flu and TBI/75Flu cohorts.ConclusionsBone marrow depletion and recovery were equally affected by 120Cy/125Flu and 60Cy/125Flu preconditioning; however, toxicity and consequently duration of hospitalization were significantly lower in the 60Cy/125Flu cohort. Patients in the 30Cy/75Flu and TBI/75Flu groups rarely developed NMA-induced adverse events; however, both regimens were not efficient in achieving deep bone marrow suppression. Among the regimens, 60Cy/125Flu preconditioning seems to achieve maximum effect with minimum toxicity.

scholarly journals Shen-Cao granules formulated based on traditional Chinese medicine alleviates bone marrow suppression caused by platinum-based anticancer reagents

Medicine ◽  
2017 ◽  
Vol 96 (19) ◽  
pp. e6818 ◽  
Author(s):  
Chunfeng Yu ◽  
Zhonghua Jiang ◽  
Aihua Hou ◽  
Yuejun Mu ◽  
Wei Liu ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Chinese Medicine ◽  
Traditional Chinese Medicine ◽  
Bone Marrow Suppression

scholarly journals Hemophagocytic Lymphohistiocytosis Complicating Erythroleukemia in a Child with Monosomy 7: A Case Report and Review of the Literature

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Samin Alavi ◽  
Maryam Ebadi ◽  
Alireza Jenabzadeh ◽  
M. T. Arzanian ◽  
Sh. Shamsian
Keyword(s):  
Bone Marrow ◽  
Case Report ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Chromosomal Abnormalities ◽  
Bone Marrow Aspiration ◽  
Review Of The Literature ◽  
Monosomy 7 ◽  
Persistent Fever ◽  
First Case ◽  
Erythroid Precursors

Herein, the first case of childhood erythrophagocytosis following chemotherapy for erythroleukemia in a child with monosomy 7 is reported. A 5-year-old boy presented with anemia, thrombocytopenia, and hepatosplenomegaly in whom erythroleukemia was diagnosed. Prolonged pancytopenia accompanied by persistent fever and huge splenomegaly and hepatomegaly became evident after 2 courses of chemotherapy. On bone marrow aspiration, macrophages phagocytosing erythroid precursors were observed and the diagnosis of HLH was established; additionally, monosomy 7 was detected on bone marrow cytogenetic examination. In conclusion, monosomy 7 can lead to erythrophagocytosis associated with erythroid leukemia and should be considered among the chromosomal abnormalities contributing to the association.

scholarly journals Isolated Gastric Myeloid Sarcoma: A Case Report and Review of the Literature

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Pankit Vachhani ◽  
Prithviraj Bose
Keyword(s):  
Bone Marrow ◽  
Acute Myeloid Leukemia ◽  
Case Report ◽  
Myeloid Leukemia ◽  
Bone Marrow Involvement ◽  
Myeloid Sarcoma ◽  
Review Of The Literature ◽  
Aged Woman ◽  
Middle Aged Woman ◽  
Acute Myeloid

Myeloid sarcoma represents the proliferation of myeloblasts of acute myeloid leukemia (AML) at extramedullary sites. While extramedullary involvement in AML is uncommon in itself, isolated myeloid sarcomas, that is, myeloid sarcomas without any bone marrow involvement, are extremely rare and pose a diagnostic and therapeutic challenge. Here, we present the case of a middle-aged woman with isolated myeloid sarcoma in the stomach—an organ seldom involved by this disease. Additionally, the literature on the epidemiology, diagnosis, pathology, prognosis, and therapeutic options in myeloid sarcomas has been reviewed.

Sign in / Sign up

Export Citation Format

Share Document